scholarly article | Q13442814 |
P819 | ADS bibcode | 2013PNAS..11020723Z |
P356 | DOI | 10.1073/PNAS.1314307110 |
P932 | PMC publication ID | 3870687 |
P698 | PubMed publication ID | 24297898 |
P50 | author | Eithan Galun | Q47008783 |
P2093 | author name string | Rami Eliakim | |
Talia Golan | |||
Eylon Yavin | |||
Hilla Giladi | |||
Ludmila Rivkin | |||
Rinat Abramovitch | |||
Ayala Hubert | |||
Yael Kopelman | |||
Abraham J Domb | |||
Abed Khalaileh | |||
Eran Goldin | |||
Adva Shemi | |||
Yael Hants | |||
Amotz Shemi | |||
Elad Horwitz | |||
Ariel Orbach | |||
Maor Lahav | |||
Sagit Arbel-Alon | |||
Zivia Brunschwig | |||
Elina Zorde Khvalevsky | |||
Alina Simerzin | |||
Alan Dancour | |||
Itzhak Haim Rachmut | |||
Racheli Gabai | |||
P2860 | cites work | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | Q24293500 |
Genetic and epigenetic alterations in pancreatic carcinogenesis | Q24598655 | ||
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
Pancreatic cancer | Q29616288 | ||
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro | Q29617927 | ||
Pancreatic cancer. | Q30490247 | ||
K-ras as a target for cancer therapy | Q36248002 | ||
Molecular genetics of pancreatic intraepithelial neoplasia | Q36829524 | ||
Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 | ||
Drug delivery systems with modified release for systemic and biophase bioavailability | Q38026125 | ||
Biopolymer nanoparticle production for controlled release of biopharmaceuticals | Q38072083 | ||
Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer | Q38073775 | ||
Biomaterial-based drug delivery systems for the controlled release of neurotrophic factors. | Q38079443 | ||
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion | Q40014102 | ||
K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment | Q40134965 | ||
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy | Q40392798 | ||
Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses. | Q40977239 | ||
Testing transgenic regulatory elements through live mouse imaging | Q45869949 | ||
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. | Q52827026 | ||
Molecular biology of pancreatic cancer | Q81973822 | ||
In vitro cell migration and invasion assays | Q84914731 | ||
P433 | issue | 51 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pancreatic cancer | Q212961 |
P1104 | number of pages | 6 | |
P304 | page(s) | 20723-20728 | |
P577 | publication date | 2013-12-02 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | Mutant KRAS is a druggable target for pancreatic cancer | |
P478 | volume | 110 |